Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction

被引:10
作者
Blais, C
Lapointe, N
Rouleau, JL
Clément, R
Gervais, N
Geadah, D
Adam, A [1 ]
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[2] Univ Toronto, Toronto Gen Hosp, Hlth Network, Div Cardiol, Toronto, ON M5G 2C4, Canada
[3] Inst Cardiol Montreal, Montreal, PQ H1T 1C8, Canada
关键词
angiotensin-converting enzyme; bradykinin; des-Arg(9)-bradykinin; heart; metallopeptidase inhibition; myocardial infarction; neutral endopeptidase 24.11;
D O I
10.1016/S0196-9781(01)00401-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purposes of this study were to evaluate and to compare the effects of simultaneous angiotensin-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) inhibition by the vasopeptidase inhibitor omapatrilat (1 mg.kg(-1).day(-1)) with those of the selective ACE inhibitor enalapril (1 mg.kg(-1).day(1)) on survival, cardiac hemodynamics, and bradykinin (BK) and des-Arg(9)-BK levels in cardiac tissues 24 h after myocardial infarction (MI) in rats. The effect of the co-administration of both B, and B, kinin receptor antagonists (2.5 mg.kg(-1.) day(-1) each) with metallopeptidase inhibitors was also evaluated. The pharmacological treatments were infused subcutaneously using micro-osmotic pumps for 5 days starting 4 days before the ligation of the left coronary artery. Immunoreactive kinins were quantified by highly sensitive and specific competitive enzyme immunoassays. The post-MI mortality of untreated rats with a large MI was high; 74% of rats dying prior to the hemodynamic study. Mortality in the other MI groups was not significantly different from that of the untreated MI rats. Cardiac BK levels were not significantly different in the MI vehicle-treated group compared with the sham-operated rats. Both omapatrilat and enalapril treatments of MI rats significantly increased cardiac BK concentrations compared with the sham-operated group (P < 0.05). However, cardiac BK levels were significantly increased only in the MI omapatrilat-treated rats compared with the MI vehicle-treated group (P < 0.01). Cardiac des-Arg(9)-BK concentrations were not significantly modified by MI, and MI with omapatrilat or enalapril treatment compared with the sham-operated group. The co-administration of both kinin receptor antagonists with MI omapatrilat- and enalapril-treated rats had no significant effect on cardiac BK and des-Arg(9)-BK levels. Thus, the significant increase of cardiac BK concentrations by omapatrilat could be related to a biochemical or a cardiac hemodynamic parameter on early (24 h) post-MI state. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:953 / 962
页数:10
相关论文
共 60 条
[1]   RAMIPRILAT INCREASES BRADYKININ OUTFLOW FROM ISOLATED HEARTS OF RAT [J].
BAUMGARTEN, CR ;
LINZ, WG ;
KUNKEL, G ;
SCHOLKENS, BA ;
WIEMER, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (02) :293-295
[2]  
BEVAN EG, 1992, J HYPERTENS, V10, P607
[3]   Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study [J].
Blais, C ;
Drapeau, G ;
Raymond, P ;
Lamontagne, D ;
Gervais, N ;
Venneman, I ;
Adam, A .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1997, 273 (05) :H2263-H2271
[4]   Absence of effect of chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations in the carrageenan-induced paw edema model in the rat [J].
Blais, C ;
Leclair, P ;
Molinaro, G ;
Adam, A .
PEPTIDES, 1999, 20 (03) :343-352
[5]  
Blais C, 1997, ARTHRITIS RHEUM, V40, P1327, DOI 10.1002/1529-0131(199707)40:7<1327::AID-ART18>3.0.CO
[6]  
2-B
[7]   Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis:: role of serum ACE and aminopeptidase P [J].
Blais, C ;
Marc-Aurèle, J ;
Simmons, WH ;
Loute, G ;
Thibault, P ;
Skidgel, RA ;
Adam, A .
PEPTIDES, 1999, 20 (04) :421-430
[8]   DIAGNOSTIC EFFICIENCY OF TROPONIN-T MEASUREMENTS IN RATS WITH EXPERIMENTAL MYOCARDIAL-CELL DAMAGE [J].
BLEUEL, H ;
DESCHL, U ;
BERTSCH, T ;
BOLZ, G ;
REBEL, W .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 1995, 47 (2-3) :121-127
[9]  
BRALET J, 1994, J PHARMACOL EXP THER, V270, P8
[10]   Angiotensin-converting enzyme inhibitors [J].
Brown, NJ ;
Vaughan, DE .
CIRCULATION, 1998, 97 (14) :1411-1420